Ambulatory - Group Practice for Specialized Psychiatric Care DATAMED
- Address
- 63 Georgi Kochev Blvd, floor 1, app.1, 5800 Pleven, Bulgaria
DATAMED - Specialized Psychiatric Care & Schizophrenia Research
The Ambulatory Group Practice for Specialized Psychiatric Care DATAMED is a dedicated research facility focused on advancing treatment options for serious mental health conditions. The center specializes in conducting long-term safety and tolerability studies for innovative psychiatric medications, with particular expertise in evaluating novel therapeutic approaches for patients with schizophrenia.
- Long-term safety and tolerability assessment of oral emraclidine (CVL-231) in adult schizophrenia patients
- Open-label clinical trials extending up to 52 weeks for comprehensive evaluation
- Specialized psychiatric care with focus on emerging pharmacological treatments
DATAMED's research infrastructure supports extended monitoring of participants with schizophrenia, enabling thorough evaluation of new medications throughout year-long treatment periods. The center's ambulatory group practice model provides patients access to cutting-edge therapeutic options while maintaining the careful oversight necessary for long-term safety studies of novel psychiatric medications like emraclidine.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Ambulatory - Group Practice for Specialized Psychiatric Care DATAMED
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Long-term Safety and Tolerability Evaluation of Emraclidine in Adult Patients with Schizophrenia: A 52-week, Phase 2, Open-label Clinical Trial | Cerevel Therapeutics LLC | Phase II | Not Recruiting | Mar 2023 | Apr 2025 |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Emraclidine | 1 | Unknown | 2023-03-08 | 2023-03-08 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.